References
Wilde MI, et al. Drugs 46: 895–924, 1993
Zohar J, et al. Drugs 43: 210–218, 1992
Palmer KJ, Benfield P. CNS Drugs 1: 57–87, 1994
Murdoch D, McTavish. Drugs 44: 604–624, 1992
McTavish D, Benfield P. Drugs 39: 136–153, 1990
Benfield P, et al. Drugs 32: 482–508, 1986
van Harten J. Clin Pharmacokinet 24: 203–220, 1993
Drugs Ther Perspect 1: 1–4, 8 Mar 1993
Goodman WK, et al. 18th Collegium Neuro-psychopharmacologicum, Nice, France, Jun 28 to Jul 1, 1992
Jenike MA, et al. Am J Psychiatry 147: 1209–1215, 1990
Greist JH. 18th Collegium Neuro-psychopharmacologicum, Nice, France, Jun 28 to Jul 1, 1992
Mallya GK, et al. Ann Clin Psychiatry 4: 77–80, 1992
Tamimi RR, et al. Ann Clin Psychiatry 3: 275–279, 1992
George MS, et al. Hum Psychopharmacol Clin Exp 8: 327–334, 1993
McDougle CJ, et al. J Clin Psychopharmacol 13: 354–358, 1993
Perse TL, et al. Am J Psychiatry 144: 1543–1548, 1987
Goodman WK, et al. Arch Gen Psychiatry 46: 36–44, 1989
Goodman WK, et al. Arch Gen Psychiatry 47: 577–585, 1989
Holland RL, et al. 18th Collegium Neuro-psychopharmacologicum, Nice, France, Jun 28 to Jul 1, 1992
Henry JA. Int Clin Psychopharmacol 6 (Suppl. 3): 41–47, 1991
Rights and permissions
About this article
Cite this article
Fluvoxamine confirms the serotonergic theory of obsessive-compulsive disorder. Drugs Ther. Perspect 3, 1–4 (1994). https://doi.org/10.2165/00042310-199403110-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199403110-00001